Phase 1 N=40 Phase 1 Study of PBTZ169
Tuberculosis
Primary: Incidence of Drug-related Adverse Events [Safety and Tolerability] — 2; 2; 1; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=56 Dose-finding Pharmacokinetic Study in Healthy Males
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Phase 1 N=23 A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects
Pharmacodynamics · Healthy Subjects
Primary: Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977. — -0.545…
Phase 1 N=39 Phase 1, TAK-648, Single-Rising Dose Study
Healthy Volunteers
Primary: Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event (TEAE) — 0; 50.0; 16.7; 0 percentage of participants
Phase 1 N=59 A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.
Malaria
Primary: The Tolerability and Safety of Ascending Single Oral Doses of MMV533 — 5; 3; 7; 4 participants
Phase 1 N=114 Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
Healthy Volunteers · Schizophrenia
Primary: Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) — 40.0; 0; 0; 0 percentage of participants
Phase 1 N=66 Phase 1 Study for IPG11406 in Health Volunteer
Inflammatory Bowel Diseases
Primary: Safety Indicators：Adverse Event — 1; 3; 2; 3 Participants
Phase 1 N=42 Phase 1 Study of SAR440894 vs Placebo
Chikungunya Virus Infection
Primary: Frequency of Adverse Events (AEs) — 5; 3; 2; 3 Participants
Phase 1 N=20 A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose — 0.92; 0.98 h*nmol/L — p=0.02
Phase 1 N=18 Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2
Healthy Volunteers
Primary: Area Under the Concentration-Time Curve (AUC 0-t) — 1490.0; 1273.0 h*ng/mL
Phase 1 N=76 Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants
Healthy Volunteers
Primary: Adverse Events — 0; 2; 3; 3 Participants
Phase 1 N=4 Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
Solid Malignancies
Primary: Total Radioactivity in Plasma Following Administration of [14C]-AZD2014 — 4013; 3415; 2901; 2693 nanogram equivalent/millilitre (ngEq/mL)
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 1 N=88 Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Adverse Events — 2; 2; 2; 1 participants
Phase 1 N=84 A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Number of Participants With All-Causality and Treatment Related Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events — 5; 3; 3; 5 participants
Phase 2 N=136 Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Advanced Solid Tumors
Primary: Determination of Recommended Phase 2 Dose (RP2D) of BVD-523 by Dose-limiting Toxicities (DLT). — 0; 0; 0; 0 Participants
Phase 1 N=66 Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
Deep Vein Thrombosis · Venous Thromboembolism
Primary: Pharmacokinetic Parameter of Apparent Systemic Clearance (CL/F) — 42.9 L/h
Phase 1 N=51 Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers
COVID-19
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity [Extrapolated] (AUC0-inf): ALG-097558 in Part A and Part C, Dabigatran (Total) in Plasma in Part B…
Phase 1 N=18 Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine
Healthy Volunteers
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) of Caffeine After a Dose of PBT2 250mg — 32775 ng*hr/mL
Phase 1 N=96 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
Healthy Male Subjects · Cardiovascular Disease
Primary: Safety and Tolerability of AZD5718 by Assessment of the Number of Participants With Adverse Events Following Oral Administration of SAD (Part A) and MAD (Part B). — 15…
Phase 2 N=66 Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions
Healthy Volunteers · Brain Lesion
Primary: Pharmacokinetic (PK) Parameter Cmax — 248.7; 524.5; 698.7; 992.0 µg/mL
Phase 1 N=8 A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers
Smoking Cessation
Primary: Number of Adverse Events — 5; 0; 1; 1 Participants
Phase 1 N=13 The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin
Epilepsy
Primary: Cmax - Maximum Steady-state Plasma Concentration — 31652 ng/mL
Phase 1 N=45 Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study
Safety, Pharmacokinetics, Pharmacodynamics, Food Effect
Primary: Safety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a…
Phase 1 N=88 Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study
Healthy Volunteers
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 0; 16.7; 33.3; 16.7 percentage of participants
Phase 1 N=24 Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants
Japanese Healthy Adult Male Participants
Primary: Number of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) — 1; 0; 2; 1 Participants
Phase 1 N=35 Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects
Healthy
Primary: Adverse Events — 0; 0 participants
Phase 2 N=20 Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects
Reflux
Primary: Reflux Episodes 0 to 3 Hours Post Meal — 15.1; 12.5; 11.0; 12.7 Episodes
Phase 1 N=6 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
Healthy
Primary: Number of Treatment Related Adverse Events — 3; 4; 0; 3 Number of events
Phase 1 N=43 A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) — 238.6; 341.3; 3831; 4891 pg/mL